Author

Rashmi Unawane

Institutions: Hackensack University Medical Center, Hackensack Meridian Health

Observed institutions: Hackensack University Medical Center, Hackensack Meridian Health, Hackensack Meridian School of Medicine

ORCID: 0000-0001-9413-5827

Observed ORCID: 0000-0001-9413-5827

OpenAlex ID: A5012444630

Exhaled breath condensate contains extracellular vesicles (EVs) that carry miRNA cargos of lung tissue origin that can be selectively purified and analyzed

2024 · Megan I. Mitchell, Iddo Z. Ben‐Dov, et al. · Journal of Extracellular Vesicles · 28

Adaptation and Evaluation of a Symptom-Monitoring Digital Health Intervention for Patients With Relapsed and Refractory Multiple Myeloma: Pilot Mixed-Methods Implementation Study

2020 · Noa Biran, Robin Anthony Kouyaté, et al. · JMIR Formative Research · 24

I-OPen: inferior outcomes of penta-refractory compared to penta-exposed multiple myeloma patients

2022 · Sarvarinder K. Gill, Rashmi Unawane, et al. · Blood Cancer Journal · 16

Development and validation of a prognostic 40-day mortality risk model among hospitalized patients with COVID-19

2021 · Donald A. Berry, Andrew Ip, et al. · PLoS ONE · 7

Patient‐reported outcomes following autologous stem cell transplant for patients with multiple myeloma

2021 · Noa Biran, Wanting Zhai, et al. · eJHaem · 5

A phase I/II study of carfilzomib, iberdomide (CC-220), and dexamethasone (KID) in patients with newly diagnosed transplant-eligible multiple myeloma.

2023 · Noa Biran, David H. Vesole, et al. · Journal of Clinical Oncology · 4

Inferior Outcomes of Patients with Quad and Penta-Refractory Multiple Myeloma (MM) Compared to Those of Patients Who Have Been Quad and Penta Exposed

2021 · Sarvarinder K Gill, Rashmi Unawane, et al. · Blood · 4

A Phase 1/2 Study of Carfilzomib, Iberdomide and Dexamethasone (KID) in Patients with Newly Diagnosed Transplant-Eligible Multiple Myeloma

2023 · Noa Biran, David H. Vesole, et al. · Blood · 3

Gut Microbiota Diversity and Composition Is Associated with High-Risk Myeloma

2023 · Rena Feinman, Ariel Aptekmann, et al. · Blood · 3

A Phase 2b Study of Selinexor in Combination with Carfilzomib, Daratumumab, or Pomalidomide in Patients with Multiple Myeloma Relapsing on Current Therapy

2023 · Noa Biran, David H. Vesole, et al. · Blood · 1

Gut Microbiome Composition Is Associated with Engraftment Syndrome in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

2022 · Rena Feinman, Ariel A. Aptekmann, et al. · Blood · 1

Value of Digital Patient Reported Outcomes (PROs) - Long-Term Management of Treatment Fatigue in Relapsed or Refractory Multiple Myeloma

2019 · Noa Biran, Emre Yucel, et al. · Blood · 1

A phase IIb study of selinexor in combination with carfilzomib, daratumumab, or pomalidomide in patients with multiple myeloma relapsing on current therapy.

2023 · Noa Biran, David H. Vesole, et al. · Journal of Clinical Oncology

Works count: 13

Citation count: 97

H-index: 5

I10-index: 3